Evidence of impaired cisapride metabolism in neonates.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print Cited Medium: Print ISSN: 0306-5251 (Print) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: London, Macmillan Journals Ltd.
    • Subject Terms:
      Cisapride/*metabolism ; Gastrointestinal Agents/*metabolism ; Microsomes, Liver/*metabolism; Adult ; Biotransformation ; Child ; Chromatography, High Pressure Liquid ; Cisapride/pharmacokinetics ; Cytochrome P-450 CYP3A ; Cytochrome P-450 Enzyme System/metabolism ; Fetus/metabolism ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Infant, Newborn ; Microsomes, Liver/enzymology ; Mixed Function Oxygenases/metabolism
    • Abstract:
      Aims: Cisapride has been shown to cause QTc prolongation in neonates in the absence of any of the known risk factors ascribed to children or adults (excessive dosage, drug-drug interactions). Our hypothesis was that the early neonatal liver may show defective elimination of cisapride resulting in its accumulation in the immature child. Owing to the difficulties associated with in vivo pharmacokinetic studies in a paediatric population, we explored the in vitro metabolism of cisapride by human cytochrome P450.
      Methods: Experiments were conducted with recombinant CYPs stably expressed in mammalian cells and with liver microsomes obtained from human foetuses, neonates, infants and adults. Cisapride metabolites were measured by high performance liquid chromatography.
      Results: The rate of biotransformation of cisapride was greater by recombinant CYP3A4 than by CYP3A7 (0.77 +/- 0.5 and 0.01 +/- 0.01 nmol metabolites formed in 24 h, respectively), whereas CYP1A1, 1A2, 2C8, 2C9 and 3A5 showed no activity. Norcisapride formation was significantly correlated with testosterone 6beta-hydroxylation, a CYP3A4 catalysed reaction (r = 0.71, P = 0.03) but not with the 16-hydroxylation of dehydroepiandrosterone, catalysed by CYP3A7 (r = 0.30, P = 0.29) by microsomes from a panel of livers from foetuses, neonates and infants. No or negligible cisapride metabolic activity was observed in microsomes from either foetuses or neonates aged less than 7 days, which contained mostly CYP3A7 and no CYP3A4. The metabolism of cisapride steadily increased after the first week of life in parallel with CYP3A4 activity to reach levels exceeding adult values.
      Conclusions: The low content of CYP3A4 in the human neonatal liver appears to be responsible for its inability to oxidize cisapride and could explain its accumulation in plasma leading to the cases of QTc prolongation reported in this paediatric population.
    • References:
      Cancer Res. 1995 Feb 15;55(4):787-91. (PMID: 7850790)
      Br J Pharmacol. 2000 Apr;129(8):1655-67. (PMID: 10780971)
      Eur J Biochem. 1997 Jul 15;247(2):625-34. (PMID: 9266706)
      Proc Natl Acad Sci U S A. 1989 Jan;86(2):462-5. (PMID: 2492107)
      Arch Dis Child Fetal Neonatal Ed. 1997 Nov;77(3):F241-3. (PMID: 9462199)
      Drugs. 1994 Jan;47(1):116-52. (PMID: 7510617)
      Clin Pharmacol Ther. 1999 Apr;65(4):395-401. (PMID: 10223776)
      Naunyn Schmiedebergs Arch Pharmakol. 1970;266(3):260-75. (PMID: 4246569)
      Pediatr Res. 2000 May;47(5):677-83. (PMID: 10813596)
      Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1678-83. (PMID: 8970354)
      J Pediatr. 1999 Mar;134(3):287-92. (PMID: 10064663)
      J Cardiovasc Electrophysiol. 1998 Oct;9(10):1109-13. (PMID: 9817562)
      J Pediatr Gastroenterol Nutr. 1997 Nov;25(5):499-506. (PMID: 9360203)
      J Pediatr Gastroenterol Nutr. 1990 Oct;11(3):420-2. (PMID: 2246729)
      Pharmacotherapy. 1998 Mar-Apr;18(2):381-5. (PMID: 9545159)
      Hepatology. 1991 Jun;13(6):1142-51. (PMID: 1904834)
      N Engl J Med. 1996 Jul 25;335(4):290-1. (PMID: 8657260)
      Eur J Biochem. 1991 Dec 5;202(2):583-8. (PMID: 1722149)
      Pediatrics. 1999 Feb;103(2):469-72. (PMID: 9925843)
      Arch Intern Med. 1995 Apr 10;155(7):765-8. (PMID: 7695465)
      Eur J Biochem. 1993 Dec 1;218(2):585-95. (PMID: 8269949)
      Drug Saf. 1996 Sep;15(3):167-75. (PMID: 8879971)
      Pediatrics. 1999 Apr;103(4 Pt 1):856-7. (PMID: 10206861)
      J Pharmacol Exp Ther. 1997 Jul;282(1):220-7. (PMID: 9223557)
      Ann Pharmacother. 1999 Jan;33(1):22-6. (PMID: 9972380)
      Am J Kidney Dis. 1997 Sep;30(3):437-9. (PMID: 9292575)
      Pharmacogenetics. 1994 Feb;4(1):11-20. (PMID: 8004129)
      Scand J Gastroenterol. 1997 Jun;32(6):541-6. (PMID: 9200284)
      Clin Pharmacol Ther. 1998 Nov;64(5):542-6. (PMID: 9834046)
      Eur J Biochem. 1998 Feb 1;251(3):893-8. (PMID: 9490065)
      Intensive Care Med. 1996 Sep;22(9):977-80. (PMID: 8905437)
      Acta Gastroenterol Belg. 1990 Jul-Aug;53(4):372-5. (PMID: 2096583)
    • Accession Number:
      0 (Gastrointestinal Agents)
      9035-51-2 (Cytochrome P-450 Enzyme System)
      EC 1.- (Mixed Function Oxygenases)
      EC 1.14.14.1 (CYP3A protein, human)
      EC 1.14.14.1 (Cytochrome P-450 CYP3A)
      EC 1.14.14.55 (CYP3A4 protein, human)
      UVL329170W (Cisapride)
    • Publication Date:
      Date Created: 20011027 Date Completed: 20011218 Latest Revision: 20240414
    • Publication Date:
      20240414
    • Accession Number:
      PMC2014576
    • Accession Number:
      10.1046/j.0306-5251.2001.01470.x
    • Accession Number:
      11678785